Friday 6 November 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.64%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
688.80
11.86
+1.75%
Follow TMO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 4 | 7 |
| 13.02% | 13.52% | 13.51% | 13.37% | ||
| 6.46% | 6.45% | 6.50% | 6.51% | ||
ROIC |
6.12% | 5.56% | 5.80% | 6.03% | |
Return on Tangible Assets |
27.84% | 37.31% | 36.57% | 32.11% | |
Average Days of Receivables |
72.91 | 74.33 | 74.45 | 74.19 | |
Free Cash Flow per Share |
16.81 | 18.25 | 19.84 | 20.64 | |
Free Cash Flow |
6,337.00 | 6,789.00 | 7,362.00 | 7,637.00 | |
Capital Expenditures |
(1,481.00) | (1,498.00) | (1,651.00) | (1,687.00) | |
| Other line items | |||||
Cash ROIC |
6.38% | 7.13% | 7.67% | 7.64% | |
Accounts Receivable Turnover |
5.21 | 5.12 | 5.14 | 5.11 | |
Accounts Payable Turnover |
7.85 | 8.37 | 8.78 | 8.99 | |
Inventory Turnover |
5.06 | 4.99 | 4.90 | 4.90 | |
Average Days of Payables |
50.23 | 45.60 | 43.49 | 40.39 | |
Days of Inventory on Hand |
75.24 | 74.95 | 74.88 | 73.83 | |
Tax Rate |
(0.07) | (0.07) | (0.08) | (0.09) | |
Research and Development Expense of Revenue |
3.14% | 3.08% | 3.03% | 2.97% | |
Selling, General and Administrative Expense of Revenue |
19.60% | 19.55% | 19.48% | 19.40% | |
Share Based Compensation of Revenue |
0.70% | 0.70% | 0.69% | 0.73% | |
Interest Coverage |
5.46 | 5.37 | 5.55 | 5.51 | |
Operating CF/Net income |
1.17 | 1.21 | 1.29 | 1.32 | |
Depreciation/Fixed assets |
0.26 | 0.26 | 0.27 | 0.29 | |
Capex/Depreciation |
(0.53) | (0.53) | (0.56) | (0.54) | |
Revenue per Share |
118.19 | 121.50 | 124.89 | 127.98 | |
Operating CF per Share |
20.74 | 22.28 | 24.29 | 25.20 | |
Capex per Share |
(3.93) | (4.03) | (4.45) | (4.56) | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 3 Nov 2026